Effectiveness of Zhibai Dihuang pill (Chinese herbal formula) in combination with western drugs in the treatment of recurrent aphthous stomatitis: A systematic review and meta-analysis.

Autor:	Peng SL; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China., Ge YM; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China., Yu XY; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China., Chen HC; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China.; Hubei Provincial Hospital of Traditional Chinese Medicine, Hubei, Wuhan, China., Song DQ; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China., Pu HY; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China., Yang P; Hubei University of Traditional Chinese Medicine, Hubei, Wuhan, China.
Jazyk:	angličtina
Zdroj:	Medicine [Medicine (Baltimore)] 2023 Oct 27; Vol. 102 (43), pp. e35180.
DOI:	10.1097/MD.0000000000035180
Abstrakt:	Background: The pain caused by recurrent aphthous stomatitis (RAS) and the recurrent nature of RAS lead to diminished quality of life for RAS patients. An alternative treatment for RAS is the oral administration of the Chinese herbal medicine Zhibai Dihuang pill (ZBDHP). Our study aims to investigate the clinical efficacy of ZBDHP when used in combination with Western medicine (WM) for the treatment of RAS and its effectiveness in preventing the recurrence of RAS. Methods: Following the PRISMA 2020 guidelines, we conducted a literature search on 7 electronic databases according to predefined criteria. The methodological quality of randomized controlled trials (RCTs) was evaluated based on the Cochrane Handbook, and data analysis was performed using RevMan 5.3 software. Results: A meta-analysis which included 7 studies and 669 participants in total was carried out in this study. The quantitative analysis revealed that the combined treatment of ZBDHP and WM has witnessed significantly improved overall clinical efficacy (RR = 1.20, 95% CI [1.12, 1.28], P < .05), reduced recurrence rate (RR = 0.24, 95% CI [0.13, 0.45], P < .05), decreased ulcer area (MD = -0.75, 95% CI [-0.91, -0.59], P < .05), and reduced pain visual simulation score (MD = -0.42, 95% CI [-0.52, -0.33], P < .05). No significant heterogeneity was observed among the studies. Qualitative analysis showed that the combination therapy significantly reduced serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 and interleukin-10, shortened ulcer healing time and pain disappearance time, with no adverse effects observed. Conclusion: It was found that the combination of ZBDHP and WM is more effective in treating RAS than the use of WM alone, which thus provides clinicians with a more optimal treatment option. However, due to limitations in the methodological quality of the included original studies and the small sample size, we hold the opinion that more rigorous and scientific clinical trials are needed to further evaluate the efficacy of ZBDHP in treating RAS. Competing Interests: The authors have no funding and conflicts of interest to disclose. (Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu